An experimental 'supercharged' form of popular GLP-1 weight-loss meds could help ease fatty liver disease, a new trial suggests.
Experimental GLP-1 med may be breakthrough against fatty liver disease retrieved 10 June 2024 from https://medicalxpress.com/news/2024-06-experimental-glp-med-breakthrough-fatty.html
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.Use this form if you have come across a typo, inaccuracy or would like to send an edit request for the content on this page. For general inquiries, please use ourThank you for taking time to provide your feedback to the editors.
Your feedback is important to us. However, we do not guarantee individual replies due to the high volume of messages.to let the recipient know who sent the email. Neither your address nor the recipient's address will be used for any other purpose. The information you enter will appear in your e-mail message and is not retained by Medical Xpress in any form.Get weekly and/or daily updates delivered to your inbox.
Medicine Research Health Research News Health Research Health Science Medicine Science
United Kingdom Latest News, United Kingdom Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Enhanced weight loss outcomes with GLP-1 analogues and bupropion/naltrexone combinationA study explores the additive effects of combining GLP-1 analog with bupropion/naltrexone on weight loss, finding potential benefits even for those initially unresponsive to monotherapy.
Read more »
Four in 10 adults with diabetes report taking a GLP-1 receptor agonistOne in eight adults (12 percent) say they have ever taken a glucagon-like peptide-1 receptor agonist (GLP-1 RA) and 6 percent say they are currently using one, according to the results of a new KFF Health Tracking Poll, released May 10.
Read more »
Study finds GLP-1 receptor agonist use increases likelihood of antidepressant prescriptionIndividuals taking glucagon-like peptide (GLP)-1 receptor agonists have a greater risk for subsequently being dispensed antidepressants, according to a study published online April 23 in Diabetes, Obesity, and Metabolism.
Read more »
GLP-1 receptor agonists effective for weight loss in obesity without diabetesThe benefit-harm balance of initiating Glucagon-like Peptide-1 (GLP-1) receptor agonists (RAs) versus a placebo intervention.
Read more »
Demographic, clinical, financial factors tied to GLP-1 agonist discontinuationSpecific demographic, clinical, and financial characteristics are associated with glucagon-like peptide 1 (GLP-1) receptor agonist discontinuation, according to a research letter published online May 24 in JAMA Network Open.
Read more »
GLP-1 may have the power to change taste sensitivity in women with obesitySemaglutide improved taste sensitivity, changed gene expression in the tongue that's responsible for taste perception, and changed the brain's response to sweet tastes, according to research presented at ENDO 2024, the Endocrine Society's annual meeting in Boston, Mass.
Read more »